Improving weight loss and cardiometabolic risk in black patients with diabetes or pre-diabetes: Rationale and protocol for a digital medicine hybrid type 1 implementation trial.

IF 2 3区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Peter T Katzmarzyk, Eboni G Price-Haywood, John W Apolzan, Kara D Denstel, Kimberly L Drews, Elise Farris, Jewel Harden-Barrios, Larry R Hearld, Emily F Mire, Corby K Martin, Robert L Newton, Maria Pisu
{"title":"Improving weight loss and cardiometabolic risk in black patients with diabetes or pre-diabetes: Rationale and protocol for a digital medicine hybrid type 1 implementation trial.","authors":"Peter T Katzmarzyk, Eboni G Price-Haywood, John W Apolzan, Kara D Denstel, Kimberly L Drews, Elise Farris, Jewel Harden-Barrios, Larry R Hearld, Emily F Mire, Corby K Martin, Robert L Newton, Maria Pisu","doi":"10.1016/j.cct.2024.107806","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The goal of the PROPEL-IT study is to conduct an effectiveness-implementation (hybrid type 1) study to 1) test the effectiveness of a digital technology focused 24-month, patient-centered precision public health approach to weight-loss, facilitated by an electronic medical record (EMR) in Black patients with obesity and type 2 diabetes mellitus or prediabetes, and 2) better understand the external validity and context for implementation.</p><p><strong>Methods: </strong>Patients in the Intensive Lifestyle Intervention (ILI) participate in a high-intensity behavioral intervention to facilitate weight loss through reducing dietary intake and increasing physical activity. The ILI is delivered by health coaches in the digital medicine program of a large health care organization facilitated by the patient portal of their EMR. Patients in the usual care (UC) group continue to receive routine medical care from their health care team. The primary outcome is percent weight change from baseline. Study implementation is guided by the Consolidated Framework for Implementation Research (CFIR) and the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) evaluative framework.</p><p><strong>Results: </strong>Patient recruitment began on August 31, 2022 and was completed on January 22, 2024. During the ∼17-month recruitment period, 352 patients were recruited and randomized (176 to ILI; 176 to UC).</p><p><strong>Conclusion: </strong>The results of this study will provide evidence on the effectiveness of a remotely delivered high-intensity weight loss program within a large health care organization, and provide important information regarding its implementation in a digital medicine setting.</p><p><strong>Clinical trials registration number: </strong>NCT05523375.</p>","PeriodicalId":10636,"journal":{"name":"Contemporary clinical trials","volume":" ","pages":"107806"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary clinical trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cct.2024.107806","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The goal of the PROPEL-IT study is to conduct an effectiveness-implementation (hybrid type 1) study to 1) test the effectiveness of a digital technology focused 24-month, patient-centered precision public health approach to weight-loss, facilitated by an electronic medical record (EMR) in Black patients with obesity and type 2 diabetes mellitus or prediabetes, and 2) better understand the external validity and context for implementation.

Methods: Patients in the Intensive Lifestyle Intervention (ILI) participate in a high-intensity behavioral intervention to facilitate weight loss through reducing dietary intake and increasing physical activity. The ILI is delivered by health coaches in the digital medicine program of a large health care organization facilitated by the patient portal of their EMR. Patients in the usual care (UC) group continue to receive routine medical care from their health care team. The primary outcome is percent weight change from baseline. Study implementation is guided by the Consolidated Framework for Implementation Research (CFIR) and the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) evaluative framework.

Results: Patient recruitment began on August 31, 2022 and was completed on January 22, 2024. During the ∼17-month recruitment period, 352 patients were recruited and randomized (176 to ILI; 176 to UC).

Conclusion: The results of this study will provide evidence on the effectiveness of a remotely delivered high-intensity weight loss program within a large health care organization, and provide important information regarding its implementation in a digital medicine setting.

Clinical trials registration number: NCT05523375.

改善黑人糖尿病或糖尿病前期患者的体重减轻和心脏代谢风险:数字医学混合1型实施试验的基本原理和方案
背景:PROPEL-IT研究的目的是进行一项有效性-实施(混合型1)研究,以1)测试数字技术为重点的24个月、以患者为中心的精确公共卫生减肥方法的有效性,该方法由电子病历(EMR)促进,适用于黑人肥胖和2型糖尿病或前驱糖尿病患者;2)更好地了解实施的外部有效性和背景。方法:强化生活方式干预(Intensive Lifestyle Intervention, ILI)患者参与高强度行为干预,通过减少饮食摄入和增加身体活动来促进体重减轻。ILI由大型医疗保健组织的数字医学项目的健康教练提供,由其电子病历的患者门户网站提供便利。常规护理(UC)组的患者继续接受其卫生保健团队的常规医疗护理。主要结果是与基线相比体重变化的百分比。研究实施由实施研究综合框架(CFIR)和覆盖、有效性、采用、实施和维护(RE-AIM)评估框架指导。结果:患者招募于2022年8月31日开始,2024年1月22日完成。在17个月的招募期内,352例患者被招募并随机分配(176例为ILI;176至UC)。结论:本研究的结果将为大型医疗机构内远程交付高强度减肥计划的有效性提供证据,并为其在数字医疗环境中的实施提供重要信息。临床试验注册号:NCT05523375。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
4.50%
发文量
281
审稿时长
44 days
期刊介绍: Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers and short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信